Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
Holding LUCD?
Track your performance easily
LUCD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.63 - $1.58
Previous Close$0.92
Volume338.40K
Average Volume (3M)225.67K
Market Cap
$49.70M
Enterprise Value$23.95M
Total Cash (Recent Filing)$39.52M
Total Debt (Recent Filing)$13.78M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 11, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding53,990,294
10 Day Avg. Volume380,194
30 Day Avg. Volume225,674
Standard Deviation0.18
R-Squared0.16
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)4.38
Price to Sales (P/S)78.39
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue37.78
Enterprise Value/Gross Profit63.54
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$3.71Price Target Upside303.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Lucid Diagnostics News
PremiumCompany Announcements
Lucid Diagnostics Unveils Key Unfiled Financial Snapshot
Bulls Say, Bears Say
Bulls Say
Clinical ValidationAnnounced positive data from its ESOGUARD BE-1 and ENVET-BE clinical studies, which has been well-received, especially the clinical validation data.
Market OpportunityLucid's minimally-invasive EsoGuard test could increase screening compliance for esophageal cancer, which has a low survival rate and currently low compliance with the standard invasive screening method.
Revenue GrowthLucid's processed test volume meaningfully increased relative to 1Q24, and efforts to improve revenue cycle management should drive revenue higher over time.
Bears Say
Market CapitalizationLucid Diagnostics currently has a small market cap, which may concern some investors despite the potential catalysts on the horizon.
Operating ExpensesLUCD's operating expenses were somewhat above estimate.
Revenue PerformanceLUCD missed consensus revenue in 2Q24 and has moderated test volume and sales-force growth until it receives final Medicare reimbursement.
---
Ownership Overview
64.13% Insiders
1.41% Mutual Funds
<0.01% Other Institutional Investors
33.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LUCD FAQ
What was Lucid Diagnostics’s price range in the past 12 months?
Lucid Diagnostics lowest stock price was $0.63 and its highest was $1.58 in the past 12 months.
What is Lucid Diagnostics’s market cap?
Currently, no data Available
When is Lucid Diagnostics’s upcoming earnings report date?
Lucid Diagnostics’s upcoming earnings report date is Nov 11, 2024 which is in 7 days.
How were Lucid Diagnostics’s earnings last quarter?
Lucid Diagnostics released its earnings results on Aug 12, 2024. The company reported -$0.2 earnings per share for the quarter, the consensus estimate of -$0.2 by $0.
Is Lucid Diagnostics overvalued?
According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued.
Does Lucid Diagnostics pay dividends?
Lucid Diagnostics does not currently pay dividends.
What is Lucid Diagnostics’s EPS estimate?
Lucid Diagnostics’s EPS estimate is -$0.2.
How many shares outstanding does Lucid Diagnostics have?
Lucid Diagnostics has 53,990,295 shares outstanding.
What happened to Lucid Diagnostics’s price movement after its last earnings report?
Lucid Diagnostics reported an EPS of -$0.2 in its last earnings report, expectations of -$0.2. Following the earnings report the stock price went up 6.329%.
Which hedge fund is a major shareholder of Lucid Diagnostics?
Currently, no hedge funds are holding shares in LUCD
---
Lucid Diagnostics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.71 (303.04% Upside)
$3.71 (303.04% Upside)
Blogger Sentiment
Bullish
LUCD Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.23%
12-Months-Change
Fundamentals
Return on Equity
-300.52%
Trailing 12-Months
Asset Growth
-19.71%
Trailing 12-Months
Company Description
Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
---
LUCD Earnings Call
Q2 2024
0:00 / 0:00
---
LUCD Stock 12 Month Forecast
Average Price Target
$3.71
▲(303.04% Upside)
Technical Analysis
Best Analysts Covering LUCD
1 Year
1 Year Success Rate
3/17 ratings generated profit
1 Year Average Return
-32.61%
reiterated a buy rating 3 months ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 17.65% of your transactions generating a profit, with an average return of -32.61% per trade.
---